中国临床药学杂志2025，Vol.34Issue(1)：28-32,5.DOI:10.19577/j.1007-4406.2025.01.005
中成药费用与肿瘤患者疾病诊断相关分组超支的相关性
Association between Chinese patent medicine and diagnosis-telated group overruns in cancer patients
摘要
Abstract
AIM To explore the association between the cost of Chinese patent medicine and diagnosis-related group(DRG)overruns in cancer patients.METHODS The multivariable logistic regression,restricted cubic spline(RCS),and two-piecewise logistic regression were used to analyze the association between Chinese patent medicines(Bailing capsules,Diyu Shengbai tablets,compound Kushen injection,Huolisu oral liquid,Kangfuxin liquid,Shengxuebao agent,Suhuang Zhike capsule,Brucea javanica oil emulsion injection,Yixue Sheng capsule and Guhong injection).A total of 1 729 patients who received chemotherapy and/or other treatments for malignant proliferative disorders and with severe or general complications and comorbidities entering the RE1A disease group from January to December 2022 in a tertiary medical institution in Mianyang City,Sichuan Province,were used as the study data.Subgroup analyses of the association between the use of Chinese patent medicine and DRG overruns were stratified by gender,age,type of participation,admission department and tumor type.RESULTS A total of 1 729 patients were included in the study and 431 patients presented with DRG overruns.The results of multivariable and univariable Logistic regression analyses indicated a significant association between Chinese patent medicine and DRG overruns(P＜0.05).Among the 10 Chinese patent medicines,the cost of compound Kushen injection and Kangfuxin injection was the independent factor that could increase the risk of DRG overruns(P＜0.05).The RCS and threshold effect analysis showed a curvilinear relationship between Chinese patent medicine and DRG overruns(P＜0.001).When the cost of Chinese patent medicine exceeded 125 yuan,it was positively associated with DRG overruns(P＜0.05).In all subgroups,the cost of Chinese patent medicines could increase the risk of DRG overruns.CONCLUSION Chinese patent medicines were associated with DRG overruns.When the cost of Chinese patent medicine exceeds 125 yuan,it is positively associated with DRG overruns(P＜0.05).Compound Kushen injection and Kangfuxin injection were independently associated with DRG overruns(P＜0.05).The rational use of Chinese patent medicines in cancer patients should be enhanced in clinical practice to reduce the cost of drugs and promote rational drug use.关键词
肿瘤患者/中成药/疾病诊断相关分组/限制性立方样条Key words
cancer patients/Chinese patent medicine/diagnosis-related group/restricted cubic spline分类
药学引用本文复制引用
赵德华,王继生,范红英,龙小庆..中成药费用与肿瘤患者疾病诊断相关分组超支的相关性[J].中国临床药学杂志,2025,34(1):28-32,5.基金项目
北京医药卫生经济研究会药物经济学&真实世界研究&药政管理专项科研促进项目(编号BJHE2023-PRP-008) （编号BJHE2023-PRP-008）
